What changed
$TJX — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ1 FY2027 (ends Apr) | reported May 20 | Rev $14.3B | EPS $1.19 vs $1.01 🟢
💡 Consensus had earnings of $1.01, but TJX delivered $1.19, a 17.8% beat, indicating the market underestimated demand and margin resilience. However, this positive surprise now appears fully reflected in the stock's premium multiple, leaving little room for upside from future beats.
🏢 Business Quality: 8/10
📊 Valuation: rich — trailing P/E 32.7x versus 10-year median ~20x; FCF yield 1.0%. EV/EBITDA likely >20x. All methods point to a premium valuation.
🔮 Catalyst: Next quarterly earnings report
⚖️ avoid — TJX is a great business but the stock is priced for perfection at 32.7x earnings with 1% FCF yield; quant ranks are dismal; risk/reward does not favor a 6-month long.